Although the recent SARS‐CoV‐2 variants showed higher adaption abilities to ACE2‐expressed cells and reduction of death rate of COVID‐19 patients, COVID‐19 threat still remains and aggressive development of antiviral drug and diagnostic platform are still necessary. The gene discussed is ACE2; the disease is COVID-19.